BioArctic AB’s partner Eisai announced that they have submitted a Marketing Authorisation Application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency in Great Britain.
